This activity is expired and is no longer available for CME credit.


NSCLC Treatment on Target: Examining New Evidence and Advances

Author(s)/Faculty: Roy S. Herbst, MD, PhD; Walter J. Curran Jr., MD; Naiyer A. Rizvi, MD; Fred R. Hirsch, MD, PhD
Release Date: 11/10/2015Expiration Date: 11/9/2016
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small cell lung cancer (NSCLC); approximately 70% of patients with NSCLC present at locally advanced stages, which are associated with poor survival rates. Current treatment paradigms for NSCLC are based on accurate staging, and comprise multimodal approaches that depend on individual patient’s profiles, including surgery, radiation therapy, chemotherapy, or immunotherapy. Overall, patients with NSCLC require personalized therapeutic strategies that are delivered by a multidisciplinary team of specialists. Given this complex scenario, it is critical for clinicians to be aware of the significant advances made in the NSCLC management landscape to optimize patients’ outcomes. In this CME activity, leading experts discuss the most recent advances in radiotherapy, immunotherapy, and molecular characterization of NSCLC.